Menu Content/Inhalt
Debio 025
Debio 025 is a cyclophilin inhibitor currently being developed for the treatment of Hepatitis C. Debio 025 is a drug with a novel mechanism of action and a lower potential for resistance selection. Debiopharm obtained positive efficacy results of a phase IIa study with Debio 025. Data indicates that Debio 025 shows an important additive anti-HCV effect when co-administered with pegylated Interferon (Peg-IFN) alpha-2a to treatment- naïve HCV patients.

Press Releases

28-Apr-2008 18-Apr-2007 31-Oct-2006 09-Feb-2006 06-Oct-2004 -> All Press Releases

Publications

01-Apr-2008 16-Mar-2008 11-Mar-2008 25-Jan-2008 13-Dec-2007 -> All Publications